{"id":419984,"date":"2021-01-25T07:03:20","date_gmt":"2021-01-25T12:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=419984"},"modified":"2021-01-25T07:03:20","modified_gmt":"2021-01-25T12:03:20","slug":"4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/","title":{"rendered":"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery"},"content":{"rendered":"
\n

\n Press Release<\/strong>\n <\/p>\n

\n 4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery<\/em><\/strong>\n <\/p>\n

\n
\n Systematic review and meta-analysis of 149 clinical trials of AAV-based gene therapies demonstrates high safety and efficacy rates <\/em>
\n <\/strong>\n <\/p>\n

\n
\n Data reinforces potential of AAV-based gene therapies to become a mainstream and potentially curative treatment modality <\/em>
\n <\/strong>\n <\/p>\n

25 January 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

LONDON & BOSTON \u2013 4BIO Capital (\u201c4BIO\u201d or \u201cthe Group\u201d), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled \u201cThe Clinical Landscape for AAV Gene Therapies<\/u><\/a>\u201d in Nature Reviews Drug Discovery<\/em>.<\/p>\n

The review, led by Dr. Dima Kuzmin in collaboration with academics from the University of Oxford and Children\u2019s Hospital of Philadelphia as well as several members of 4BIO\u2019s management and advisory teams, analyses 149 unique adeno-associated virus (AAV) gene therapy clinical trials, determining current key trends and depicting the impact of clinical trials on the gene therapy field. This is the first systematic review and meta-analysis that establishes transition probabilities, cumulative safety, and efficacy data for AAV gene therapies.<\/p>\n

Gene therapy using AAV as a vector has emerged as a novel therapeutic modality with significant clinical developments made over the past 20 years, including the treatment of over 3000 patients, showing its potential for substantial disease modification in many monogenic disorders, and perhaps even cures. The most commonly used serotype, AAV2, has produced vast amounts of safety and efficacy evidence, indicating its ability to be readily used within the gene therapy space. In addition, decreasing clinical trial duration, which reflects increased comfort from regulators, and the growing number of successful clinical trials focusing on treating diseases of the central nervous system (CNS), reiterates the potential of AAV gene therapy as a safe, well tolerated and efficacious therapeutic modality.<\/p>\n

The authors show that AAV gene therapy is generally safe and well tolerated, with no clinical trials failing to reach their primary safety endpoints prior to the cut-off date of the review. Additionally, whilst sample sizes are still relatively small, the existing data indicates the success rates of gene therapy development are significantly higher than the average for all modalities. For example, the transition probability for a drug progressing from an investigative new drug (IND) to a new drug application (NDA) is 31% for ophthalmology gene therapies as compared to 24% across all modalities; 43% vs. 16% in metabolic diseases; 56% vs 47% in haematology; and 30% vs. 19% in neurology.<\/p>\n

However, the authors conclude that drawbacks remain and further innovations, such as better manufacturing, an ongoing switch to engineered capsids and synthetic promoters could lead AAV gene therapies to advance from the primary targets of the retina, liver, muscle and brain into other major organs and therefore into the next stage of clinical significance.<\/p>\n

\n Dr. Dima Kuzmin, Managing Partner at 4BIO Capital, said: <\/strong>
\n \u201cThe analysis of vast amounts of clinical trial data has allowed us to establish the safety, tolerability and efficacy of AAV gene therapy, and consider it as a potential curative modality. Whilst certain challenges, such as uncertainty with regards to durability of response to gene therapy and potential viral vector liver toxicity are still yet to be overcome, it is clear that AAV gene therapy has the potential to become an effective mainstream therapeutic option.\u201d<\/em>\n <\/p>\n

-Ends-<\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n\n
\n 4BIO Capital<\/strong>\n <\/td>\n+44 (0) 203 427 5500
info@4biocapital.com<\/td>\n<\/tr>\n
\n \u00a0<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n AccessAlpha Worldwide LLC<\/strong>\n <\/td>\n+1 (312) 585 6000
4BIO@AccessAlpha.com<\/td>\n<\/tr>\n
\n \u00a0<\/strong>\n <\/td>\n\n \u00a0<\/strong>\n <\/td>\n<\/tr>\n
\n Consilium Strategic Communications<\/strong>
\n
Amber Fennell, Olivia Manser, Lizzie Seeley<\/td>\n		+44 (0)20 3709 5700
4biocapital@consilium-comms.com<\/td>\n<\/tr>\n<\/table>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n About 4BIO Capital<\/strong>\n <\/p>\n

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.<\/p>\n

4BIO\u2019s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.<\/p>\n

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature<\/em>, The Lancet<\/em>, Cell<\/em>, and the New England Journal of Medicine<\/em>. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.<\/p>\n

For more information, please visit www.4biocapital.com<\/u><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Press Release 4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery Systematic review and meta-analysis of 149 clinical trials of AAV-based gene therapies demonstrates high safety and efficacy rates Data reinforces potential of AAV-based gene therapies to become a mainstream and potentially curative treatment modality 25 January 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LONDON & BOSTON \u2013 4BIO Capital (\u201c4BIO\u201d or \u201cthe Group\u201d), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled \u201cThe Clinical Landscape for AAV Gene Therapies\u201d in Nature Reviews Drug Discovery. The review, led by Dr. Dima Kuzmin in collaboration with academics from the University of Oxford and Children\u2019s Hospital of Philadelphia as well … <\/p>\n

Continue reading “4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-419984","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\n4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Press Release 4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery Systematic review and meta-analysis of 149 clinical trials of AAV-based gene therapies demonstrates high safety and efficacy rates Data reinforces potential of AAV-based gene therapies to become a mainstream and potentially curative treatment modality 25 January 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LONDON & BOSTON \u2013 4BIO Capital (\u201c4BIO\u201d or \u201cthe Group\u201d), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled \u201cThe Clinical Landscape for AAV Gene Therapies\u201d in Nature Reviews Drug Discovery. The review, led by Dr. Dima Kuzmin in collaboration with academics from the University of Oxford and Children\u2019s Hospital of Philadelphia as well … Continue reading "4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T12:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery\",\"datePublished\":\"2021-01-25T12:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/\"},\"wordCount\":718,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/\",\"name\":\"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx\",\"datePublished\":\"2021-01-25T12:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery - Market Newsdesk","og_description":"Press Release 4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery Systematic review and meta-analysis of 149 clinical trials of AAV-based gene therapies demonstrates high safety and efficacy rates Data reinforces potential of AAV-based gene therapies to become a mainstream and potentially curative treatment modality 25 January 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LONDON & BOSTON \u2013 4BIO Capital (\u201c4BIO\u201d or \u201cthe Group\u201d), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled \u201cThe Clinical Landscape for AAV Gene Therapies\u201d in Nature Reviews Drug Discovery. The review, led by Dr. Dima Kuzmin in collaboration with academics from the University of Oxford and Children\u2019s Hospital of Philadelphia as well … Continue reading \"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T12:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery","datePublished":"2021-01-25T12:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/"},"wordCount":718,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/","name":"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx","datePublished":"2021-01-25T12:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MjUyMyM0MDA4NTcwNzYjNzAwMDExOTIx"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/4bio-capitals-review-of-aav-gene-therapy-clinical-trials-published-in-nature-reviews-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"4BIO Capital\u2019s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=419984"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419984\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=419984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=419984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=419984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}